Huntington's Disease News and Research

Latest Huntington's Disease News and Research

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

Presentation of results from open-label extension study of Xenazine

Presentation of results from open-label extension study of Xenazine

Research may lead to new therapeutic treatments for Huntington's disease

Research may lead to new therapeutic treatments for Huntington's disease

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

BrainStorm Cell Therapeutics secures funds for ALS clinical trials

BrainStorm Cell Therapeutics secures funds for ALS clinical trials

Clive Svendsen to receive American Academy of Neurology Sheila Essey Award for his research on ALS

Clive Svendsen to receive American Academy of Neurology Sheila Essey Award for his research on ALS

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Huntington's disease: Latrepirdine appears well-tolerated and beneficial

Huntington's disease: Latrepirdine appears well-tolerated and beneficial

Dimebon drug associated with improved cognitive function in patients with Huntington's disease

Dimebon drug associated with improved cognitive function in patients with Huntington's disease

AMRI announces fourth-quarter and full-year 2009 results

AMRI announces fourth-quarter and full-year 2009 results

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

Mouse model demonstrates cell-to-cell connections between implanted stem cells and diseased cells

Mouse model demonstrates cell-to-cell connections between implanted stem cells and diseased cells

Scientists uncover a key cellular mechanism that alters brain cell function in Huntington's disease

Scientists uncover a key cellular mechanism that alters brain cell function in Huntington's disease

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

The American Journal of Pathology: Highlights from February 2010 issue

The American Journal of Pathology: Highlights from February 2010 issue

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

HSF1A stimulates more protein chaperones and reduces protein misfolding

HSF1A stimulates more protein chaperones and reduces protein misfolding

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.